BioPharmSignal logoBioPharmSignal

Biotech News

Brainstorm Cell Therapeutics Secures Second $1 Million Strategic Placement; Total $2 Million Raised In February

Brainstorm Cell Therapeutics Inc. (BCLI)Brainstorm Cell Therapeutics Inc.Company update

BCLI (BCLI) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is bcli.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

BCLIBrainstorm Cell Therapeutics Inc.2026-06-02 13:00 EST

BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine

BCLIBrainstorm Cell Therapeutics Inc.2026-05-28 11:45 EST

BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors

ANNXAnnexon, Inc.2026-07-30 20:01 EST

Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance

TNXPTonix Pharmaceuticals2026-06-08 11:00 EST

Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives

DNLIDenali Therapeutics2026-08-06 20:01 EST

Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

IKTInhibikase Therapeutics2026-07-14 12:00 EST

Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility

PASGPassage Bio2026-06-24 20:05 EST

Passage Bio and Remix Therapeutics Announce Merger Agreement

DNLIDenali Therapeutics2026-06-18 12:00 EST

Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million

JSPRJasper Therapeutics2026-06-01 12:00 EST

Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

PTIXProtagenic Therapeutics2026-05-19 08:15 EST

Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner

View all latest news

Brainstorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics is a cell-therapy company focused on neurological disease, especially ALS. Its platform has long been tied to a high-risk, high-conviction neurodegeneration story.

Recent company news

BCLIBrainstorm Cell Therapeutics Inc.2026-07-28 12:00 EST

BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman

BCLIBrainstorm Cell Therapeutics Inc.2026-06-02 13:00 EST

BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine

BCLIBrainstorm Cell Therapeutics Inc.2026-05-28 11:45 EST

BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors

BCLIBrainstorm Cell Therapeutics Inc.2026-05-19 12:00 EST

BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market

BCLIBrainstorm Cell Therapeutics Inc.2026-05-15 20:05 EST

BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

Stock data

Close
0.80 USD
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States